Breast Cancer Clinical Trial
Official title:
Cone Beam Breast CT for Breast Cancer Screening
Up to one thousand and twenty-eight (1028) patients from screening and diagnostic population will be enrolled and consented to participate in the study to create an enriched data set. These women will be enrolled from annual screening population and diagnostic workup population. The enrolled patient will undergo KBCT scans within 4 weeks of her screening or diagnostic mammography exam and before breast biopsy occurs if biopsy is needed.
Status | Recruiting |
Enrollment | 1024 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 29, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 30 Years and older |
Eligibility | Inclusion Criteria: Screening Group: - Female sex of any ethnicity - Age 40 years or older - Scheduled for a routine screening mammography exam within 4 weeks. Diagnostic Group: - Female sex of any ethnicity - Age 20 years or older - Have an abnormality detected by Breast Self Exam (BSE), or Clinical Breast Exam (CBE), or have an abnormality detected by an imaging modality. - Will undergo diagnostic mammography, prior to breast biopsy (if needed). Exclusion Criteria: - Pregnancy - Lactation - Unknown pregnancy status AND - has refused pregnancy testing and - has refused to sign a pregnancy test waiver - Women who are unable or unwilling to understand or to provide informed consent - Women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker. - Women who are unable to tolerate study constraints. - Women who have received radiation treatments to the thorax or breast area for malignant and nonmalignant conditions, such as (but not limited to): - Treatment for enlarged thymus gland as an infant - Irradiation for benign breast conditions, including breast inflammation after giving birth - Treatment for Hodgkin's disease - Women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram. - Women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to): - Tuberculosis - Severe scoliosis Additional exclusion criteria due to machine limitations - Patient's body weight is over the limit of the scanner table (440 lbs. or 200kg) |
Country | Name | City | State |
---|---|---|---|
United States | Women's Imaging Specialists | Dacula | Georgia |
United States | Knoxville Comprehensive Breast Center | Knoxville | Tennessee |
United States | Port Orange Imaging Center | Port Orange | Florida |
United States | The Howard Center for Women's Health | Tifton | Georgia |
Lead Sponsor | Collaborator |
---|---|
Koning Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiation Dose | The radiation dose of CBBCT imaging and Mammography imaging | 3 months after the CBBCT imaging and Mammography imaging | |
Primary | Recall Rates | The overall recall rates of CBBCT imaging and Mammography imaging | 3 months after CBBCT image review and Mammography image review |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |